S E Hufton
Overview
Explore the profile of S E Hufton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fennell B, Darmanin-Sheehan A, Hufton S, Calabro V, Wu L, Muller M, et al.
J Mol Biol
. 2010 May;
400(2):155-70.
PMID: 20450918
The shark antigen-binding V(NAR) domain has the potential to provide an attractive alternative to traditional biotherapeutics based on its small size, advantageous physiochemical properties, and unusual ability to target clefts...
2.
van den Beucken T, van Neer N, Sablon E, Desmet J, Celis L, Hoogenboom H, et al.
J Mol Biol
. 2001 Jul;
310(3):591-601.
PMID: 11439026
Ligands specific for B7.1 (CD80) and B7.2 (CD86) have applications in disease indications that require inhibition of T-cell activity. As we observed significant sequence and structural similarity between the B7-binding...
3.
Hufton S, Moerkerk P, de Bruine A, Arends J, Hoogenboom H
Biochem Soc Trans
. 2000 Jul;
26(1):S5.
PMID: 10909763
No abstract available.
4.
Chames P, Hufton S, Coulie P, Uchanska-Ziegler B, Hoogenboom H
Proc Natl Acad Sci U S A
. 2000 Jul;
97(14):7969-74.
PMID: 10884427
Antitumor antibodies with the same specificity as cytotoxic T lymphocytes that recognize antigenic peptides encoded by tumor-associated genes and presented by MHC class I molecules would be valuable tools to...
5.
Hufton S, van Neer N, van den Beuken T, Desmet J, Sablon E, Hoogenboom H
FEBS Lett
. 2000 Jun;
475(3):225-31.
PMID: 10869561
We have explored the possibilities of using human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) as a single immunoglobulin fold-based scaffold for the generation of novel binding ligands. To obtain a...
6.
Hufton S, Moerkerk P, Meulemans E, de Bruine A, Arends J, Hoogenboom H
J Immunol Methods
. 2000 Jan;
231(1-2):39-51.
PMID: 10648926
The selection of phage displayed cDNA repertoires on an immobilised target has been reported to be an efficient way to rapidly identify interacting partners. To date, however, only a few...
7.
Hufton S, Moerkerk P, Brandwijk R, de Bruine A, Arends J, Hoogenboom H
FEBS Lett
. 1999 Dec;
463(1-2):77-82.
PMID: 10601642
As a step towards understanding the complex differences between normal cells and cancer cells, we have used suppression subtractive hybridization (SSH) to generate a profile of genes overexpressed in primary...
8.
Nuttall S, Rousch M, Irving R, Hufton S, Hoogenboom H, Hudson P
Proteins
. 1999 Jul;
36(2):217-27.
PMID: 10398368
We have designed and engineered the human cytotoxic T-lymphocyte associated protein-4 (CTLA-4) variable (V-like) domain to produce a human-based protein scaffold for peptide display. First, to test whether the CTLA-4...
9.
De Haard H, van Neer N, Reurs A, Hufton S, Roovers R, Henderikx P, et al.
J Biol Chem
. 1999 Jun;
274(26):18218-30.
PMID: 10373423
We report the design, construction, and use of the first very large non-immunized phage antibody library in Fab format, which allows the rapid isolation and affinity analysis of antigen-specific human...
10.
Hoogenboom H, de Bruine A, Hufton S, Hoet R, Arends J, Roovers R
Immunotechnology
. 1998 Jul;
4(1):1-20.
PMID: 9661810
In recent years, the use of display vectors and in vitro selection technologies has transformed the way in which we generate ligands, such as antibodies and peptides, for a given...